{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:09:24Z","timestamp":1785190164462,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:p>Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.<\/jats:p>","DOI":"10.1097\/md.0000000000038767","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:52:19Z","timestamp":1719586339000},"page":"e38767","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy"],"prefix":"10.1097","volume":"103","author":[{"given":"Gbolahan","family":"Olatunji","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kokori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel Charles","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi","family":"Omoworare","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Lagos State University College of Medicine, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyin","family":"Olatunji","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Western Illinois University, Macomb, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimezirim","family":"Ezeano","sequence":"additional","affiliation":[{"name":"Department of Health, University of North Texas, Health Science Centre, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babawale","family":"Emmanuel Adeoba","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Griffith College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Chidera","family":"Stanley","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Calabar, Calabar, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awoyinfa Michael","family":"Oluwatobiloba","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Lagos, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omidiran Basit","family":"Oluwademilade","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Afe Babalola University, Ado-Ekiti, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kale Mekoya","family":"Shimelis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Addis Ababa University, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale","family":"Olanisa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health Centre, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0004-7389","authenticated-orcid":false,"given":"Nicholas","family":"Aderinto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"R2-20260223","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","article-title":"Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen.","volume":"12","author":"Coelho","year":"2022","journal-title":"Neurol Ther"},{"key":"R3-20260223","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"R4-20260223","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","article-title":"Gertza MSMWCSBHBDKCWLO. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.","volume":"12","author":"Morie","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R5-20260223","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14656566.2018.1554648","article-title":"An indirect treatment comparison of the efficacy of Patisiran and Tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.","volume":"20","author":"Plant\u00e9-Bordeneuvea","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R6-20260223","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/eurheartjsupp\/suac104","article-title":"The treatment of amyloidosis is being refined.","volume":"24","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"R7-20260223","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care.","volume":"16","author":"Luigetti","year":"2020","journal-title":"Therap Clin Risk Manag"},{"key":"R8-20260223","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"R9-20260223","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.","volume":"93","author":"Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R10-20260223","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","article-title":"Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future.","volume":"18","author":"Obici","year":"2021","journal-title":"Neurotherapeutics"},{"key":"R11-20260223","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval.","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"R12-20260223","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A narrative review of the role of transthyretin in health and disease.","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol Ther"},{"key":"R13-20260223","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval.","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"R14-20260223","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R15-20260223","doi-asserted-by":"crossref","first-page":"e030512","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of Technetium-99m-Pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of Eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy.","volume":"13","author":"Yu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R16-20260223","first-page":"S1071-9164(23)00894-1","article-title":"Effect of Eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis.","author":"Masri","year":"2023","journal-title":"J Card Fail"},{"key":"R17-20260223","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"R18-20260223","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, Vutrisiran, in healthy subjects.","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260223","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:02:03Z","timestamp":1771884123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":19,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038767","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}